22.6 C
New York
Saturday, June 13, 2026

Tag: launch

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.1  

FREELANDER 8 Makes First Public Appearance Ahead of Official Abu Dhabi Launch

FREELANDER 8 made its first public appearance at the Abu Dhabi Investment Forum held at The Peninsula Shanghai on June 11, 2026.

To Go Fast and Far: Why Africa’s Businesses Are Rebuilding Technology in 2026

CAPE TOWN, South Africa, June 13, 2026 /PRNewswire/ -- This is exactly why Junkies Coder an Africa-based software engineering company has launched its Agentic AI...

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type...

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53,000 people in the U.S. alone, and there are currently no approved treatment options for the disease.

Crypto News Today: AlphaPepe Unveils AlphaSwap Early Access as Bitcoin Price Prediction Eyes $250,000

MONACO, June 12, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after the project unveiled AlphaSwap Early Access, giving users the ability to trade selected pairs across Ethereum and BSC through Uniswap and PancakeSwap routers. The update gives AlphaPepe a working trading layer before launch, while the future AlphaSwap router remains part of the project’s next product expansion.

SpaceX IPO Project Unlimited (Weiss Ratings’ Michael Robinson Disruptors & Dominators Newsletter) Elon’s Trillion Dollar Plan to Save AI

SPCX IPO live: Weiss Ratings' Disruptors & Dominators covers orbital AI supply chain research. 4 bonus reports. Weiss Ratings LLC.

Wells Fargo Foundation Provides $1 Million Grant to Expand Capital Access for Broward County Entrepreneurs

Ascendus to deploy $900,000 in loans and pair every dollar with hands-on coaching, from Prospera and other partners, supporting an estimated 160 local jobs...

Lotus Tech Announces Operational and Earnings Reporting Updates

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) -- Lotus Technology Inc. (Nasdaq: LOT) (“Lotus Tech” or the “Company”), a leading global intelligent and luxury mobility provider, today provided an update on recent developments and announced the temporary suspension of the publication of earnings releases for the first quarter and third quarter of fiscal year 2026.

PreludeDx™ Achieves New Milestones for DCIS Patients and DCISionRT® Testing

LAGUNA HILLS, Calif., June 12, 2026 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in precision diagnostics for breast cancer, today highlighted a new milestone...

PowerA and Meridian GMT Announce Strategic Partnership at FlightSimExpo 2026

New "Fueled by PowerA" initiative takes flight, bringing advanced flight simulation experiences to more players worldwideWOODINVILLE, Wash., June 12, 2026 /PRNewswire/ -- PowerA, a...

Allegheny Health Network’s Biomarker Moonshot Cancer Research Program Marks Five-Year Milestone, Enrolling More Than 11,000 Patients Across All Cancer Types

Systemwide research initiative uses blood‑based genomics to improve early detection and personalize cancer treatmentPITTSBURGH, June 12, 2026 /PRNewswire/ -- Allegheny Health Network (AHN) Cancer...

Morvulikent Officially Launches Its Advanced AI Trading Platform for the Next Generation of Automated Trading in 2026

New York City, June 12, 2026 (GLOBE NEWSWIRE) --

In 2026 Morvulikent has officially announced the launch of its new AI-powered trading platform, introducing a next-generation automated trading environment designed to simplify financial market participation through artificial intelligence, real-time data analysis, and intelligent automation.

Cincinnati Reds and Avocados From Peru Launch Ultimate Summer Baseball Sweepstakes Featuring Toyota Tacoma Grand Prize

Fans can enter for a chance to win a custom Toyota Tacoma, VIP Reds Experiences, and more.
Fans can enter for a chance to win a custom Toyota Tacoma, VIP Reds Experiences, and more.

EVA Air President Clay Sun Named First Taiwanese Member of IATA Board of Directors

TAIPEI, June 12, 2026 /PRNewswire/ -- The International Air Transport Association (IATA) has elected EVA Air President Clay Sun to its Board of Directors,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsLaunch